Friday, August 12, 2016

#Mining News: #CordobaMinerals (TSX-V: $CDB; OTCQX: $CDBMF) and HPX Discover Lateral Extensions of #Copper-#Gold Mineralization at #Colombia's Alacran Deposit in #Colombia

#Mining News: #CordobaMinerals (TSX-V: $CDB; OTCQX: $CDBMF) and HPX Discover Lateral Extensions of #Copper-#Gold Mineralization at #Colombia's Alacran Deposit in #Colombia



TORONTO, ONTARIO - August 12, 2016 (Investorideas.com Newswire) Mining News Alert- Cordoba Minerals Corp. (TSX-V: CDB; OTCQX: CDBMF) and its joint venture partner, High Power Exploration Inc. ("HPX"), a private mineral exploration company indirectly controlled by mining entrepreneur Robert Friedland's Ivanhoe Industries, LLC, report that ongoing drilling at the Alacran Copper-Gold Deposit has discovered significant new lateral extensions to known copper-gold mineralization, indicating significant potential for a large tonnage open-pit copper-gold resource.
Drilling in the northern area of the Alacran Deposit, within the Company’s San Matias Copper-Gold Project in Colombia, has outlined significant widths of high-grade coppergold mineralization starting near surface. Mineralization now extends over 250 metres laterally and remains open in all directions, highlighting the significant potential for further resource expansion over the 1.3 kilometres of strike drilled to date. Two active drill fences over 500 metres and 700 metres to the south of the initial lateral step-out drilling and east of previous diamond drilling where ASA-037 intersected 42 metres of 2.83 grams per tonne (g/t) gold and 0.43% copper, have identified large zones of visible chalcopyrite-pyrite-magnetite mineralization, indicating the potential for similar lateral extensions including prospective gold-rich zones, significantly adding to the overall size of the copper-gold mineralized system.

Alacran drilling highlights (refer to Table 1):
  • ACD-012: 224 metres @ 0.50% copper and 0.17 g/t gold, including 78 metres @ 0.74% copper and 0.35 g/t gold.
  • ACD-010: 171 metres @ 0.51% copper and 0.18 g/t gold; including 35 metres @ 0.80% copper and 0.23 g/t gold.
  • ACD-013: 160 metres @ 0.47% copper and 0.11 g/t gold including 78 metres @ 0.71% copper and 0.15 g/t gold.
  • ACD-014: 109 metres @ 0.51% copper and 0.31 g/t gold including 54 metres @ 0.90% copper and 0.49 g/t gold.
Mario Stifano, President and CEO of Cordoba, commented, “The ongoing 10,000-metre drilling program at Alacran is continuing to successfully expand the size and scale of the deposit both on strike and laterally and remains open, making Alacran potentially a large-tonnage open-pit deposit in what we believe is a prolific copper-gold system at San Matias. We have started Phase Two of the proprietary Typhoon technology deployment that will cover 14 square kilometres of the San Matias Copper-Gold Project including the southern area of Alacran, as we continue to aggressively explore the district with a total 20,000-metre diamond drilling program.”
The Northern Alacran area was the focus of the five drillholes that were targeting both lateral and vertical extensions from previous drilling. Four holes successfully intersected large zones of copper-gold mineralization associated with both shallow and high-grade zones, and the mineralization remains open in all directions (Figure 2). The following is a discussion of each intersection:
  • Drillhole ACD-010 (Figure 3) was located on section 855720mN where it tested the up-dip extensions of drillhole ACD-007 (169 metres @ 0.48% copper and 0.33 g/t gold) as a 50 metre step-out. ACD-010 successfully intersected a large, continuous zone of copper-gold mineralization of 171 metres @ 0.51% copper and 0.18 g/t gold, including 35 metres @ 0.80% copper and 0.23 g/t gold, that remains open both up- and down-dip on section. This mineralization remains open to the south down plunge and up-dip on section.
  • Drillhole ACD-012 (Figure 3) was also collared on section 855720mN and tested between drillholes ASA-025 (downdip: 68 metres @ 0.50% copper and 0.09 g/t gold; and 131 metres @ 0.52% copper and 0.24 g/t gold) and ACD-007 (updip: 169 metres @ 0.48% copper and 0.33 g/t gold). ACD-012 successfully intersected a large and continuous zone of copper-gold mineralization of 224 metres @ 0.50% copper and 0.17 g/t gold, including 78 metres @ 0.74% copper and 0.35 g/t gold, and indicates that the copper-gold mineralization on this section has good continuity with respect to grade and thickness.
  • Drillhole ACD-013 (Figure 4) was located on section 855760mN where it has tested the up-dip lateral extensions to known copper-gold mineralization in drillhole ACD-009 (150m @ 0.73% copper and 0.49 g/t gold) with a 50-metre step-out. ACD-013 successfully intersected a large, continuous zone of coppergold mineralization of 160 metres @ 0.47% copper and 0.11 g/t gold, including 78 metres @ 0.71% copper and 0.15 g/t gold.
  • Drillhole ACD-014 (Figure 4) was also located on section 855760mN and was collared 100 metres east of ACD-013 to test the lateral up-dip extensions. ACD- 014 successfully intersected a large and continuous zone of copper-gold mineralization of 109 metres @ 0.51% copper and 0.31 g/t gold, including 54 metres @ 0.90% copper and 0.49 g/t gold, that remains open to the east and up-dip.
  • Drillhole ACD-011 was located on section 855960mN and was designed to test a large IP chargeability anomaly. Drilling intersected a large interval of altered sediments, volcanic rocks and diorite intrusive with abundant disseminated pyrite but no significant intersection of copper-gold mineralization. Interpretation of the geology and alteration suggests the drillhole was located on the northern side of an east-west trending fault structure that offsets the copper-gold deposit at the most northern parts of the known mineralization. The copper-gold mineralization is interpreted to be located further east, where a coincident gold-and copper-insoil anomaly is located.
Together, drillholes ACD-013 and ACD-014 indicate the lateral extent of the Alacran Copper-Gold Deposit is significantly larger to the east than previously suggested, demonstrating potential for additional lateral extensions along the entire strike of the Alacran Deposit.
Alacran Copper-Gold System
The Alacran copper-gold system is located within the Company’s San Matias Copper- Gold Project in the Department of Cordoba, Colombia. The Alacran system is located on a topographic high in gently rolling topography, optimal for potential open-pit mining. Access and infrastructure are considered favourable. Alacran is approximately two kilometres southwest of the Company’s Montiel porphyry copper-gold discovery, where drilling interested 101 metres of 1.0% copper and 0.65 g/t gold, and two kilometres northwest of the Costa Azul porphyry copper-gold discovery, where drilling interested 87 metres of 0.62% copper and 0.51 g/t gold (Figure 1). The copper-gold mineralization at Alacran is associated with stratabound replacement of a marine volcano-sedimentary sequence in the core of a faulted antiformal fold structure. The deposit comprises moderately to steeply-dipping stratigraphy that is mineralized as a series of sub-parallel replacement-style or skarn zones and associated disseminations (Figure 2). The copper-gold mineralization is composed of multiple overprinting hydrothermal events with the main ore phase comprised of chalcopyrite-pyrrhotite-pyrite that appears to overprint a large-scale early magnetite metasomatic event.
High temperature potassic feldspar-biotite-amphibole-albite alteration in the host geological sequence, indicates that the copper-gold mineralization is proximal to a source intrusion. At least two intrusive phases, locally occurring as sills, confirm an intrusive source for the mineralizing fluids. The overall size and complexity of the hydrothermal system indicates a significant mineralization event. Mineralization occurs within all members of the sedimentary and volcanic sequence, where it can be traced over a strike length of greater than 1,300 metres and local thickness of more than 90 metres true-width, and upwards of 180 metres true-width, from the current drilling and surface sampling (Figure 3).
Alacran Exploration
A soil sampling program covering the entire Alacran project area has been completed consisting of 50-metre spaced sampling centres on 100-metre spaced sampling lines. The results for both copper-in-soil (Figure 5) and gold-in-soil (Figure 6) anomalism indicate the copper-gold mineralized system at Alacran to be much more extensive than previously suggested with dimensions of coincident copper and gold enrichment of significant levels being evident over +1,500 metres strike and with lateral widths of over 800 metres. The soil anomalism is particularly evident to the east of the previous drilling programs carried out at Alacran and has been the incentive for the lateral step-out drilling that has successfully located significant lateral extents to the Alacran coppergold mineralization. The accelerated and expanded diamond drilling program at Alacran is to test these lateral extensions over the entire strike length of known mineralization and additional targets as an ongoing aggressive drilling campaign.
About San Matias Project
The San Matias Copper-Gold Project comprises a 20,000-hectare land package on the inferred northern extension of the richly endowed Mid-Cauca Belt in Colombia. The project contains several known areas of porphyry copper-gold mineralization, coppergold skarn mineralization and vein-hosted, gold-copper mineralization. Porphyry mineralization at the San Matias Project incorporates high-grade zones of copper-gold mineralization hosted by diorite porphyries containing secondary biotite alteration and various orientations of sheeted and stockwork quartz-magnetite veins with chalcopyrite and bornite. The copper-gold skarn mineralization at Alacran is associated with stratabound replacement of a marine volcano-sedimentary sequence. The nature of mineralization encountered at San Matias is similar to other large high-grade coppergold deposits.
Technical Information
The technical information has been reviewed, verified and compiled by Christian J. Grainger, PhD, a Qualified Person for the purpose of NI 43-101. Dr. Grainger is a geologist with over 15 years in the minerals mining, consulting, exploration and research industries. Dr. Grainger is a Member of the Australian Institute of Geoscientists (AIG) and Australian Institute of Mining and Metallurgy (AusIMM).
All samples have been prepared and assayed at ALS laboratory in Medellin, Colombia with gold assays being carried out as 50-gram Fire-Assays with AAS finish and all trace elements and base metals being assayed using four Acid Digest with ICP-MS finish. Copper-equivalent values have been calculated using a US$1,350 per ounce gold price and US$2.20 per pound copper price. The company utilizes an industry-standard QA/QC program. HQ and NQ diamond drill-core is sawn in half with one-half shipped to a sample preparation lab. The remainder of the core is stored in a secured storage facility for future assay verification. Blanks, duplicates and certified reference standards are inserted into the sample stream to monitor laboratory performance and a portion of the samples are periodically checked for assayed result quality.
Joint Venture Agreement
The San Matias Project is a joint venture between Cordoba and HPX, a private mineral exploration company founded by mining entrepreneur Robert Friedland. HPX has entered Phase Two of the Joint Venture Agreement, whereby HPX can earn a 51% interest in the San Matias Project by spending an additional C$10.5 million bringing total expenditures to C$19 million and can earn up to a 65% interest in the project by carrying it to feasibility.
About High Power Exploration
HPX is a privately owned, metals-focused exploration company deploying proprietary in-house geophysical technologies to rapidly evaluate buried geophysical targets. The HPX technology cluster comprises geological and geophysical systems for targeting, modelling, survey optimization, acquisition, processing and interpretation. HPX has a highly experienced board and management team led by Co-Chairman and Chief Executive Officer Robert Friedland, President Eric Finlayson, a former head of exploration at Rio Tinto, and co-chaired by Ian Cockerill, a former Chief Executive Officer of Gold Fields Ltd. For further information, please visitwww.hpxploration.com.
About Cordoba Minerals
Cordoba Minerals Corp. is a Toronto-based mineral exploration company focused on the exploration and acquisition of copper and gold projects in Colombia. Cordoba has a joint venture with High Power Exploration on the highly prospective, district-scale San Matias Copper-Gold Project located at sea level with excellent infrastructure and near operating open-pit mines in the Department of Cordoba. For further information, please visit www.cordobaminerals.com.











ON BEHALF OF THE COMPANY
Mario Stifano, President and CEO
Cordoba Minerals Corp.
Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release includes certain “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, "forecast", “expect”, "potential", "project", "target", "schedule", budget" and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the potential of the Company’s properties are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forwardlooking statements are based on a number of material factors and assumptions. Important factors that could cause actual results to differ materially from Company’s expectations include actual exploration results, changes in project parameters as plans continue to be refined, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, uninsured risks, regulatory changes, delays or inability to receive required approvals, and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate and accordingly readers are cautioned not to place undue reliance on forward-looking statements which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure – this  news is a paid for standard news release - $100
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



Thursday, August 11, 2016

#CordobaMinerals (TSX-V: $CDB; OTCQX: $CDBMF) and HPX Discover Significant Lateral Extensions of #Copper-#Gold Mineralization at the Alacran Deposit in #Colombia

#CordobaMinerals (TSX-V: $CDB; OTCQX: $CDBMF) and HPX Discover Significant Lateral Extensions of #Copper-#Gold Mineralization at the Alacran Deposit in #Colombia

TORONTO, ONTARIO - August 11, 2016 (Investorideas.com Newswire) Cordoba Minerals Corp. (TSX-V: CDB; OTCQX: CDBMF) (“Cordoba” or the “Company”) and its joint venture partner, High Power Exploration Inc. ("HPX"), a private mineral exploration company indirectly controlled by mining entrepreneur Robert Friedland’s Ivanhoe Industries, LLC, are pleased to announce that ongoing drilling at the Alacran Copper-Gold Deposit has discovered significant new lateral extensions to known copper-gold mineralization, indicating significant potential for a large tonnage open-pit copper-gold resource.
Drilling in the northern area of the Alacran Deposit, within the Company’s San Matias Copper-Gold Project in Colombia, has outlined significant widths of high-grade coppergold mineralization starting near surface. Mineralization now extends over 250 metres laterally and remains open in all directions, highlighting the significant potential for further resource expansion over the 1.3 kilometres of strike drilled to date. Two active drill fences over 500 metres and 700 metres to the south of the initial lateral step-out drilling and east of previous diamond drilling where ASA-037 intersected 42 metres of 2.83 grams per tonne (g/t) gold and 0.43% copper, have identified large zones of visible chalcopyrite-pyrite-magnetite mineralization, indicating the potential for similar lateral extensions including prospective gold-rich zones, significantly adding to the overall size of the copper-gold mineralized system.
Alacran drilling highlights (refer to Table 1):
  • ACD-012: 224 metres @ 0.50% copper and 0.17 g/t gold, including 78 metres @ 0.74% copper and 0.35 g/t gold.
  • ACD-010: 171 metres @ 0.51% copper and 0.18 g/t gold; including 35 metres @ 0.80% copper and 0.23 g/t gold.
  • ACD-013: 160 metres @ 0.47% copper and 0.11 g/t gold including 78 metres @ 0.71% copper and 0.15 g/t gold.
  • ACD-014: 109 metres @ 0.51% copper and 0.31 g/t gold including 54 metres @ 0.90% copper and 0.49 g/t gold.
Mario Stifano, President and CEO of Cordoba, commented, “The ongoing 10,000-metre drilling program at Alacran is continuing to successfully expand the size and scale of the deposit both on strike and laterally and remains open, making Alacran potentially a large-tonnage open-pit deposit in what we believe is a prolific copper-gold system at San Matias. We have started Phase Two of the proprietary Typhoon technology deployment that will cover 14 square kilometres of the San Matias Copper-Gold Project including the southern area of Alacran, as we continue to aggressively explore the district with a total 20,000-metre diamond drilling program.”
The Northern Alacran area was the focus of the five drillholes that were targeting both lateral and vertical extensions from previous drilling. Four holes successfully intersected large zones of copper-gold mineralization associated with both shallow and high-grade zones, and the mineralization remains open in all directions (Figure 2). The following is a discussion of each intersection:
  • Drillhole ACD-010 (Figure 3) was located on section 855720mN where it tested the up-dip extensions of drillhole ACD-007 (169 metres @ 0.48% copper and 0.33 g/t gold) as a 50 metre step-out. ACD-010 successfully intersected a large, continuous zone of copper-gold mineralization of 171 metres @ 0.51% copper and 0.18 g/t gold, including 35 metres @ 0.80% copper and 0.23 g/t gold, that remains open both up- and down-dip on section. This mineralization remains open to the south down plunge and up-dip on section.
  • Drillhole ACD-012 (Figure 3) was also collared on section 855720mN and tested between drillholes ASA-025 (downdip: 68 metres @ 0.50% copper and 0.09 g/t gold; and 131 metres @ 0.52% copper and 0.24 g/t gold) and ACD-007 (updip: 169 metres @ 0.48% copper and 0.33 g/t gold). ACD-012 successfully intersected a large and continuous zone of copper-gold mineralization of 224 metres @ 0.50% copper and 0.17 g/t gold, including 78 metres @ 0.74% copper and 0.35 g/t gold, and indicates that the copper-gold mineralization on this section has good continuity with respect to grade and thickness.
  • Drillhole ACD-013 (Figure 4) was located on section 855760mN where it has tested the up-dip lateral extensions to known copper-gold mineralization in drillhole ACD-009 (150m @ 0.73% copper and 0.49 g/t gold) with a 50-metre step-out. ACD-013 successfully intersected a large, continuous zone of coppergold mineralization of 160 metres @ 0.47% copper and 0.11 g/t gold, including 78 metres @ 0.71% copper and 0.15 g/t gold.
  • Drillhole ACD-014 (Figure 4) was also located on section 855760mN and was collared 100 metres east of ACD-013 to test the lateral up-dip extensions. ACD- 014 successfully intersected a large and continuous zone of copper-gold mineralization of 109 metres @ 0.51% copper and 0.31 g/t gold, including 54 metres @ 0.90% copper and 0.49 g/t gold, that remains open to the east and up-dip.
  • Drillhole ACD-011 was located on section 855960mN and was designed to test a large IP chargeability anomaly. Drilling intersected a large interval of altered sediments, volcanic rocks and diorite intrusive with abundant disseminated pyrite but no significant intersection of copper-gold mineralization. Interpretation of the geology and alteration suggests the drillhole was located on the northern side of an east-west trending fault structure that offsets the copper-gold deposit at the most northern parts of the known mineralization. The copper-gold mineralization is interpreted to be located further east, where a coincident gold-and copper-insoil anomaly is located.
Together, drillholes ACD-013 and ACD-014 indicate the lateral extent of the Alacran Copper-Gold Deposit is significantly larger to the east than previously suggested, demonstrating potential for additional lateral extensions along the entire strike of the Alacran Deposit.
Alacran Copper-Gold System
The Alacran copper-gold system is located within the Company’s San Matias Copper- Gold Project in the Department of Cordoba, Colombia. The Alacran system is located on a topographic high in gently rolling topography, optimal for potential open-pit mining. Access and infrastructure are considered favourable. Alacran is approximately two kilometres southwest of the Company’s Montiel porphyry copper-gold discovery, where drilling interested 101 metres of 1.0% copper and 0.65 g/t gold, and two kilometres northwest of the Costa Azul porphyry copper-gold discovery, where drilling interested 87 metres of 0.62% copper and 0.51 g/t gold (Figure 1). The copper-gold mineralization at Alacran is associated with stratabound replacement of a marine volcano-sedimentary sequence in the core of a faulted antiformal fold structure. The deposit comprises moderately to steeply-dipping stratigraphy that is mineralized as a series of sub-parallel replacement-style or skarn zones and associated disseminations (Figure 2). The copper-gold mineralization is composed of multiple overprinting hydrothermal events with the main ore phase comprised of chalcopyrite-pyrrhotite-pyrite that appears to overprint a large-scale early magnetite metasomatic event.
High temperature potassic feldspar-biotite-amphibole-albite alteration in the host geological sequence, indicates that the copper-gold mineralization is proximal to a source intrusion. At least two intrusive phases, locally occurring as sills, confirm an intrusive source for the mineralizing fluids. The overall size and complexity of the hydrothermal system indicates a significant mineralization event. Mineralization occurs within all members of the sedimentary and volcanic sequence, where it can be traced over a strike length of greater than 1,300 metres and local thickness of more than 90 metres true-width, and upwards of 180 metres true-width, from the current drilling and surface sampling (Figure 3).
Alacran Exploration
A soil sampling program covering the entire Alacran project area has been completed consisting of 50-metre spaced sampling centres on 100-metre spaced sampling lines. The results for both copper-in-soil (Figure 5) and gold-in-soil (Figure 6) anomalism indicate the copper-gold mineralized system at Alacran to be much more extensive than previously suggested with dimensions of coincident copper and gold enrichment of significant levels being evident over +1,500 metres strike and with lateral widths of over 800 metres. The soil anomalism is particularly evident to the east of the previous drilling programs carried out at Alacran and has been the incentive for the lateral step-out drilling that has successfully located significant lateral extents to the Alacran coppergold mineralization. The accelerated and expanded diamond drilling program at Alacran is to test these lateral extensions over the entire strike length of known mineralization and additional targets as an ongoing aggressive drilling campaign.
About San Matias Project
The San Matias Copper-Gold Project comprises a 20,000-hectare land package on the inferred northern extension of the richly endowed Mid-Cauca Belt in Colombia. The project contains several known areas of porphyry copper-gold mineralization, coppergold skarn mineralization and vein-hosted, gold-copper mineralization. Porphyry mineralization at the San Matias Project incorporates high-grade zones of copper-gold mineralization hosted by diorite porphyries containing secondary biotite alteration and various orientations of sheeted and stockwork quartz-magnetite veins with chalcopyrite and bornite. The copper-gold skarn mineralization at Alacran is associated with stratabound replacement of a marine volcano-sedimentary sequence. The nature of mineralization encountered at San Matias is similar to other large high-grade coppergold deposits.
Technical Information
The technical information has been reviewed, verified and compiled by Christian J. Grainger, PhD, a Qualified Person for the purpose of NI 43-101. Dr. Grainger is a geologist with over 15 years in the minerals mining, consulting, exploration and research industries. Dr. Grainger is a Member of the Australian Institute of Geoscientists (AIG) and Australian Institute of Mining and Metallurgy (AusIMM).
All samples have been prepared and assayed at ALS laboratory in Medellin, Colombia with gold assays being carried out as 50-gram Fire-Assays with AAS finish and all trace elements and base metals being assayed using four Acid Digest with ICP-MS finish. Copper-equivalent values have been calculated using a US$1,350 per ounce gold price and US$2.20 per pound copper price. The company utilizes an industry-standard QA/QC program. HQ and NQ diamond drill-core is sawn in half with one-half shipped to a sample preparation lab. The remainder of the core is stored in a secured storage facility for future assay verification. Blanks, duplicates and certified reference standards are inserted into the sample stream to monitor laboratory performance and a portion of the samples are periodically checked for assayed result quality.
Joint Venture Agreement
The San Matias Project is a joint venture between Cordoba and HPX, a private mineral exploration company founded by mining entrepreneur Robert Friedland. HPX has entered Phase Two of the Joint Venture Agreement, whereby HPX can earn a 51% interest in the San Matias Project by spending an additional C$10.5 million bringing total expenditures to C$19 million and can earn up to a 65% interest in the project by carrying it to feasibility.
About High Power Exploration
HPX is a privately owned, metals-focused exploration company deploying proprietary in-house geophysical technologies to rapidly evaluate buried geophysical targets. The HPX technology cluster comprises geological and geophysical systems for targeting, modelling, survey optimization, acquisition, processing and interpretation. HPX has a highly experienced board and management team led by Co-Chairman and Chief Executive Officer Robert Friedland, President Eric Finlayson, a former head of exploration at Rio Tinto, and co-chaired by Ian Cockerill, a former Chief Executive Officer of Gold Fields Ltd. For further information, please visitwww.hpxploration.com.
About Cordoba Minerals
Cordoba Minerals Corp. is a Toronto-based mineral exploration company focused on the exploration and acquisition of copper and gold projects in Colombia. Cordoba has a joint venture with High Power Exploration on the highly prospective, district-scale San Matias Copper-Gold Project located at sea level with excellent infrastructure and near operating open-pit mines in the Department of Cordoba. For further information, please visit www.cordobaminerals.com.













ON BEHALF OF THE COMPANY
Mario Stifano, President and CEO
Cordoba Minerals Corp.
Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release includes certain “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, "forecast", “expect”, "potential", "project", "target", "schedule", budget" and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions and includes the negatives thereof. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the potential of the Company’s properties are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forwardlooking statements are based on a number of material factors and assumptions. Important factors that could cause actual results to differ materially from Company’s expectations include actual exploration results, changes in project parameters as plans continue to be refined, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, uninsured risks, regulatory changes, delays or inability to receive required approvals, and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ from those described in forward-looking statements, there may be other factors that cause such actions, events or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate and accordingly readers are cautioned not to place undue reliance on forward-looking statements which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
More Info:
Investorideas.com Newswire
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure – this  news is a paid for standard news release - $100
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Medical Technology News: Aethlon Medical (Nasdaq: $AEMD) Announces Zika Virus Data




Medical Technology News: Aethlon Medical (Nasdaq: $AEMD) Announces Zika Virus Data

In vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier




SAN DIEGO, CA, August 11, 2016 -- (Investorideas Newswire) Aethlon Medical, Inc. (Nasdaq:AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.  At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study.  The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours. 

The studies were conducted with the Zika viral strain that has recently spread from South America to ravage Puerto Rico and likely responsible for the first wave of infections that have begun to occur in the United States.  Zika has been declared a global health threat by the World Health Organization and is not addressed with a proven drug or vaccine therapy.  According to the CDC, more than 7,300 Americans have been diagnosed with Zika virus infection, including 1,825 individuals in the continental U.S. and Hawaii.  Researchers have linked Zika virus infection with Guillain-Barre syndrome, a severe neurological disorder that can cause paralysis.  In pregnant women, Zika can cause Microcephaly, which results in babies being born with a small head and underdeveloped brain. Zika infection has also been associated with Arthrogryposis, a condition that results in deformities of joints in the arms and legs of newborns.

"As a result of our research team’s validation of Zika capture, we have further reinforced the potential of our Hemopurifier® to be a first line of defense against the growing list of infectious viral pathogens that are not addressed with traditional drug or vaccine therapies," stated Aethlon Chairman and CEO, Jim Joyce.

Aethlon also disclosed that it entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to validate the in vitro capture of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), which was discovered to be infectious to man in 2012 and has an approximate 30% mortality rate.  Like Zika virus, MERS-CoV is not addressed with a proven drug or vaccine.   The agreement is based on the modification of a contract milestone underlying the Company’s participation in DARPA’s Dialysis-Like Therapeutics program.

Broad-Spectrum Virus Capture Validations
Zika virus is the most recent of four significant arboviruses that have spread to the Western Hemisphere.  It follows Dengue, which first emerged aggressively in the 1990s; West Nile virus, which emerged in 1999; and Chikungunya, which emerged in 2013. "Arbovirus" is a descriptive term applied to hundreds of predominantly RNA viruses that are transmitted by arthropods, most notably through mosquitoes.  As a result of the Zika study, the Hemopurifier® has now demonstrated the capture of each of these four arboviruses.

Beyond Zika, Dengue, Chikungunya and West Nile virus, the Hemopurifier has also been validated to capture Monkey pox, which serves as models for human Smallpox infection.  Specific to pandemic influenza threats, the Hemopurifier has been validated to capture the H5N1 avian flu virus, H1N1 swine flu virus, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims. 

Human Treatment Experiences
In regards to human studies, Hemopurifier therapy has previously been administered to individuals infected with Ebola, Hepatitis C and HIV.  In the case of Ebola, the successful treatment of a comatose physician with multiple organ failure contributed to the emergency use clearance of the Hemopurifier® by the FDA and the government of Canada.


About Aethlon Medical
Aethlon Medical (Nasdaq: AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.


The Hemopurifier® in Cancer
Upwards of ninety percent of all cancer-related deaths are attributed to metastasis; the spread of cancer from a primary site of origin to other organs or areas of the body.  The mechanism of how tumors metastasize to distant sites in the body has long been one of cancer's greatest mysteries. That mystery was recently solved when circulating particles known as tumor-derived exosomes were discovered to be the seeds that promote the spread and growth of cancer metastasis.

Aethlon initiated its tumor-derived exosome research at a time when the medical community believed exosomes were merely cellular debris with no biological function.  Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care.  Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma.

Beyond their role in metastasis, researchers have also published mounting evidence that tumor-derived exosomes contribute to tumorigenesis (the formation of cancer), cancer progression, angiogenesis (creation of blood vessels to fuel tumor growth), immune evasion, and resistance to radiation and chemotherapeutic drugs.  Recent discoveries also reveal that exosomes may contribute to bacterial and viral pathogenesis, the progression of Alzheimer and Parkinson's diseases, the spread of prion proteins, and numerous inflammatory conditions.

The Hemopurifier® in Infectious Disease
Emerging pathogens pose a significant threat to mankind.  Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with proven antiviral drug or vaccine therapies.  Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming is expected to accelerate the emergence of future pandemics.  In response, the U.S. Department of Health and Human Services (HHS) has established an initiative to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.

To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).  In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."

Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.  Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919.  In vitro studies of other viral threats are ongoing.

Aethlon has also demonstrated that the Hemopurifier captures the bacteria toxins lipopolysaccharide (LPS) and lipoteichoic acid (LTA).  These studies were conducted under a contract with the Defense Advanced Research Projects Agency (DARPA) related to the treatment of sepsis.



About Exosome Sciences
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical (Nasdaq: AEMD), is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases.  The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids.  In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection.  Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to detect Chronic Traumatic Encephalopathy (CTE) in living individuals.  In a study of former National Football League (NFL) players, TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports. TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed.   Visit www.exosomesciences.com  for additional details.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including any products relating to the Zika virus, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:
Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc.
212-986-6667

Visit this Company: www.AethlonMedical.com

More info on AEMD at Investorideas.com: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD August 11, 2016 – one month of PR. News publication and social media – two thousand five hundred  

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.